Please provide your email address to receive an email when new articles are posted on . Among patients with cardiogenic shock, there was no difference between the inotropic agents milrinone and ...
A head-to-head comparison of inotropes in the setting of cardiogenic shock revealed no clear victor, with milrinone and dobutamine providing similar outcomes in the randomized DOREMI trial. A ...
A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent over the ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results